Béraud et al. Muzio, M., Polentarutti, N., Bosisio, D., Prahladan, M. K., and Mantovani, A. (2000). Toll-like receptors: a growing family of immune receptors that are differentially expressed and regulated by different leukocytes. J. Leukoc. Biol. 67, 450–456. Nagatsu, T., Mogi, M., Ichinose, H., and Togari, A. (2000). Cytokines in Parkinson’s disease. J. Neural Transm. Suppl. 143–151. Naiki, H., Higuchi, K., Hosokawa, M., and Takeda, T. (1989). Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1. Anal. Biochem. 177, 244–249. O’Neill, L. A., Bryant, C. E., and Doyle, S. L. (2009). Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol. Rev. 61, 177–197. Ouchi, Y., Yagi, S., Yokokura, M., a n d S a k a m o t o, M . ( 2 0 0 9 ) . Neuroinflammation in the living brain of Parkinson’s disease. Parkinsonism Relat. Disord. 15(Suppl. 3), S200–S204. Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., and Torizuka, T. (2005). Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann. Neurol. 57, 168–175. Ousman, S. S., Wang, J., and Campbell, I. L. (2005). Differential regulation of interferon regulatory factor (IRF)-7 and IRF-9 gene expression in the central nervous system during viral infection. J. Virol. 79, 7514–7527. Paine, A., Eiz-Vesper, B., Blasczyk, R., and Immenschuh, S. (2010). Signaling to heme oxygenase-1 and its anti- inflammatory therapeutic potential. Biochem. Pharmacol. 80, 1895–1903. Parihar, M. S., Parihar, A., Fujita, M., Hashimoto, M., and Ghafourifar, P. (2008). Mitochondrial associa- tion of alpha-synuclein causes oxi- dative stress. Cell. Mol. Life Sci. 65, 1272–1284. Parihar, M. S., Parihar, A., Fujita, M., Hashimoto, M., and Ghafourifar, P. (2009). Alpha-synuclein overexpres- sion and aggregation exacerbates impairment of mitochondrial func- tions by augmenting oxidative stress in human neuroblastoma cells. Int. J. Biochem. Cell Biol. 41, 2015–2024. Periquet, M., Fulga, T., Myllykangas, L., Schlossmacher, M. G., and Feany, M. B. (2007). Aggregated alpha- synuclein mediates dopaminergic neurotoxicity in vivo. J. Neurosci. 27, 3338–3346. Perrin, R. J., Woods, W. S., Clayton, D. F., and George, J. M. (2001). Exposure to long chain polyunsaturated fatty acids triggers rapid multimeriza- tion of synucleins. J. Biol. Chem. 276, 41958–41962. Polymeropoulos, M. H., Higgins, J. J., Golbe, L. I., Johnson, W. G., Ide, S. E., Di Iorio, G., Sanges, G., Stenroos, E. S., Pho, L. T., Schaffer, A. A., Lazzarini, A. M., Nussbaum, R. L., and Duvoisin, R. C. (1996). Mapping of a gene for Parkinson’s disease to chromosome 4q21-q23. Science 274, 1197–1199. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I., and Nussbaum, R. L. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276, 2045–2047. Qian, L., Hong, J. S., and Flood, P. M. (2006). Role of microglia in inflammation-mediated degenera- tion of dopaminergic neurons: neu- roprotective effect of interleukin 10. J. Neural Transm. Suppl. 367–371. Reed-Geaghan, E. G., Savage, J. C., Hise, A. G., and Landreth, G. E. (2009). CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}- stimulated microglial activation. J. Neurosci. 29, 11982–11992. Reynolds, A. D., Kadiu, I., Garg, S. K., Glanzer,J.G.,Nordgren,T.,Ciborowski, P., Banerjee, R., and Gendelman, H. E. (2008). Nitrated alpha-synuclein and microglial neuroregulatory activities. J. Neuroimmune Pharmacol. 3, 59–74. Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T.,Watanabe, M., Takeda, A., Tomiyama, H., Nakashima, K., Hasegawa, K., Obata, F., Yoshikawa, T., Kawakami, H., Sakoda, S.,Yamamoto, M., Hattori, N., Murata, M., Nakamura, Y., and Toda, T. (2009). Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat. Genet. 41, 1303–1307. Sawada, M., Imamura, K., and Nagatsu, T. (2006).Role of cytokines in inflamma- tory process in Parkinson’s disease. J. Neural Transm. Suppl. 373–381. Schipper, H. M. (2004). Heme oxygenase expression in human central nervous system disorders. Free Radic. Biol. Med. 37, 1995–2011. Schipper, H. M., Liberman, A., and Stopa, E.G.(1998).Neural heme oxygenase-1 expression in idiopathic Parkinson’s disease. Exp. Neurol. 150, 60–68. Seong, S. Y., and Matzinger, P. (2004). Hydrophobicity: an ancient damage- associated molecular pattern that ini- tiates innate immune responses. Nat. Rev. Immunol. 4, 469–478. Sharon, R., Bar-Joseph, I., Frosch, M. P., Walsh, D. M., Hamilton, J. A., and Selkoe, D. J. (2003). The formation of highly soluble oligomers of alpha- synuclein is regulated by fatty acids and enhanced in Parkinson’s disease. Neuron 37, 583–595. Shlyakhtenko, L. S., Gall, A. A., Filonov, A., Cerovac, Z., Lushnikov, A., and Lyubchenko, Y. L. (2003). Silatrane- based surface chemistry for immo- bilization of DNA, protein-DNA complexes and other biological mate- rials. Ultramicroscopy 97, 279–287. Shlyakhtenko, L. S., Potaman, V. N., Sinden, R. R., Gall, A. A., and Lyubchenko, Y. L. (2000). Structure and dynamics of three-way DNA junc- tions: atomic force microscopy studies. Nucleic Acids Res. 28, 3472–3477. Shtilerman, M. D., Ding, T. T., and Lansbury, P. T. Jr. (2002). Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concen- tration induce Parkinson’s disease? Biochemistry 41, 3855–3860. Simon-Sanchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S. W., Hernandez, D. G., Kruger, R., Federoff, M., Klein, C., Goate, A., Perlmutter, J., Bonin, M., Nalls, M. A., Illig, T., Gieger, C., Houlden, H., Steffens, M., Okun, M. S., Racette, B. A., Cookson, M. R., Foote, K. D., Fernandez, H. H., Traynor, B. J., Schreiber, S., Arepalli, S., Zonozi, R., Gwinn, K., Van Der Brug, M., Lopez, G., Chanock, S. J., Schatzkin, A., Park, Y., Hollenbeck, A., Gao, J., Huang, X., Wood, N. W., Lorenz, D., Deuschl, G., Chen, H., Riess, O., Hardy, J. A., Singleton, A. B., and Gasser, T. (2009). Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat. Genet. 41, 1308–1312. Singleton, A., Gwinn-Hardy, K., Sharabi, Y., Li, S. T., Holmes, C., Dendi, R., Hardy, J., Crawley, A., and Goldstein, D. S. (2004). Association between cardiac denervation and parkinson- ism caused by alpha-synuclein gene triplication. Brain 127, 768–772. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra,A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, C., Cookson, M. R., Muenter, M., Baptista, M., Miller, D., Blancato, J., Hardy, J., and Gwinn-Hardy, K. (2003). Alpha-synuclein locus trip- lication causes Parkinson’s disease. Science 302, 841. Frontiers in Neuroscience | Neurodegeneration α-Synuclein and TLRs Song, D. D., Shults, C. W., Sisk, A., Rockenstein, E., and Masliah, E. (2004). Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp. Neurol. 186, 158–172. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997). Alpha-synuclein in Lewy bodies. Nature 388, 839–840. Stewart, C. R., Stuart, L. M., Wilkinson, K., Van Gils, J. M., Deng, J., Halle, A., Rayner, K. J., Boyer, L., Zhong, R., Frazier, W. A., Lacy-Hulbert, A., El Khoury, J., Golenbock, D. T., and Moore, K. J. (2010). CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 11, 155–161. Su, X., Federoff, H. J., and Maguire-Zeiss, K. A. (2009). Mutant alpha-synuclein overexpression mediates early proin- flammatory activity. Neurotox. Res. 16, 238–254. Su, X., Maguire-Zeiss, K. A., Giuliano, R., Prifti, L., Venkatesh, K., and Federoff, H. J. (2008). Synuclein activates micro- glia in a model of Parkinson’s disease. Neurobiol. Aging 29, 1690–1701. Sugama, S.,Yang, L., Cho, B. P., Degiorgio, L. A., Lorenzl, S., Albers, D. S., Beal, M. F., Volpe, B. T., and Joh, T. H. (2003). Age-related microglial activa- tion in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res. 964, 288–294. Tanaka, S., Ide, M., Shibutani, T., O h t a k i , H . , Nu m a z aw a , S . , Shioda, S., and Yoshida, T. (2006). Lipopolysaccharide-induced micro- glial activation induces learning and memory deficits without neuronal cell death in rats. J. Neurosci. Res. 83, 557–566. Theodore, S., Cao, S., Mclean, P. J., and Standaert, D. G. (2008). Targeted over- expression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson dis- ease. J. Neuropathol. Exp. Neurol. 67, 1149–1158. Thomas, M. P., Chartrand, K., Reynolds, A., Vitvitsky, V., Banerjee, R., and Gendelman, H. E. (2007). Ion channel blockade attenuates aggre- gated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson’s disease. J. Neurochem. 100, 503–519. Tsigelny, I. F., Crews, L., Desplats, P., Shaked,G.M.,Sharikov,Y.,Mizuno,H., Spencer, B., Rockenstein, E., Trejo, M., June 2011 | Volume 5 | Article 80 | 10